Press Releases
Vanessa Research starts Phase 2 clinical trials in early 2018 for Shylicine™
HAMDEN, CT, UNITED STATES - Nov 15, 2017 - Vanessa Research, Inc. (VRI), an emerging healthcare and biotech company, attended its first meeting with the European Medicines Agency in October and will now start its Phase 2 clinical trials in the first quarter of 2018 for the rare disease Microvillus Inclusion Disease (MVID).
Beginning clinical trials is a tremendous accomplishment. It not only signifies the confidence in our work but it also validates that our team is on the right track in creating a treatment for MVID, said Dr. Ludmila Kvochina, Director of Research Laboratory.
About the Clinical Trial
The primary objective of the Phase 2 clinical trials is to test the clinical activity and efficacy of Shylicine for the treatment of diarrhea in MVID. In addition, VRI expects to verify the reduction in patient dependency on TPN and register changes in intestinal morphology. The trial is anticipated to last 8 weeks.
Call to Action
Due to the rarity of the disease, our trials will be open to participants worldwide. Currently, hospitals in the UK, Netherlands, Turkey, United States and Saudi Arabia will be expected to enroll patients. If you want to learn more about Shylicine and our clinical trials plans, please email us or visit our educational website at: http://mvid.vanessaresearch.com/
About Vanessa Research
Vanessa Research is based in Hamden, Connecticut, with offices in London, England and Budapest, Hungary. VRI was founded on the desire to build a 21st century, sustainable, innovative, entrepreneurial organization by bringing together a collection of diverse scientists, engineers, business professionals and academics to create solutions in medicine.
The companys mission is to give hope where none existed by delivering healthcare products that improve and increase access to quality care while decreasing costs.
Contact Information:
Benjamin P. Szabo, J.D.
Company Secretary
Vanessa Research, Inc.
925 Sherman Avenue,
Hamden, CT, 06514 U.S.A.
benjamin.szabo@vanessaresearch.com
www.vanessaresearch.com
*Shylicine and give hope where none existed are trademarks and copyrights of Vanessa Research, Inc.
